news & resources

Publications and Presentations

Peer-Reviewed Publications


Herold KC et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. NEJM. Published online June 9, 2019.

Kuhn C, Weiner HL. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. 2016 Jul;8(8):889-906.

Hagopian W et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901-3908.

Sherry N et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized, placebo-controlled trial. Lancet. 2011;378(9790):487-497.


Abadie, V., et al. IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease. Nature (2020).

Cellier C et al. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Gastroenterol Hepatol. 2019 Dec;4(12):960-970. doi: 10.1016/S2468-1253(19)30265-1. Epub 2019 Sep 4.

Lähdeaho ML et al. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol Hepatol. 2019 Dec;4(12):948-959. doi: 10.1016/S2468-1253(19)30264-X. Epub 2019 Sep 4.

Syage JA, et al., Determination of gluten consumption in celiac disease patients on a gluten-free diet. Am J Clin Nutr. 2018 Feb 1;107(2):201-207.

Guandalini S, et al., Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis. Dig Dis Sci. 2016 Oct;61(10):2823-2830.

Ettersperger J, et al., Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. Immunity. 2016 Sep 20;45(3):610-625.

Shah S et al., Patient perception of treatment burden is high in celiac disease compared with other common conditions. Am J Gastroenterol. 2014 Sep;109(9):1304-11.

Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev. 2014 Jul;260(1):221-34.

Malamut G, et al., IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. Clin Invest. 2010 Jun;120(6):2131-43.


Doerfler et al. Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy – Methods & Clinical Development. (2016) 3, 15053.

Franks SE et al. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016 Dec;43:39-45.

Veri MC et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 2010;62(7):1933-1943.

Su K et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol. 2007 Mar 1;178(5):3272-3280.


Dunne, J.L., et al, Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes, Diabetologia. 2019.

Hyöty et al., Developing a vaccine for type 1 diabetes by targeting coxsackievirus B, Expert Rev Vaccines. 2018 Nov 19:1-13.

Laitinen et al., Coxsackievirus B1 Is Associated With Induction of beta-Cell Autoimmunity That Portends Type 1 Diabetes, Diabetes. 2014 Feb;63(2):446-55.

Oikarinen et al., Virus Antibody Survey in Different European Populations Indicates Risk Association Between Coxsackievirus B1 and Type 1 Diabetes, Diabetes. 2014 Feb;63(2):655-62.

Romero. Pediatric Group B Coxsackievirus Infections, Curr Top Microbiol Immunol. 2008; 323:223-39.

Sioofy-Khojine et al., Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes, Diabetologia. 2018 May;61(5):1193-1202.

Stone et al., A Coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes, Diabetologia. 2018 Feb;61(2):476-481.



Jacobstein. Toward the Development of Medication for Celiac Disease. Canadian Celiac Association 2020.


Merrill et al. Top-line Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE). ACR 2018 (Late-Breaker).

Chen et al. Immunomodulatory Effects of MGD010, a DART® Molecule Targeting Human B-cell CD32B and CD79B. EULAR 2017.